Investor – Page 2 – Optimum Strategic Communications

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

3 October 2024/in Client news

Financing to advance lead asset RTX001, an engineered, pro-regenerative macrophage therapy with first-in-class potential for end-stage liver disease, into the Phase I/II EMERALD study Proceeds also strengthen manufacturing capabilities and support macrophage therapy pipeline growth in inflammatory and fibrotic indications beyond liver disease Paul Sekhri, seasoned life sciences executive with decades of drug development and […]

Weekly wrap-up: $100m Series B financing for a bivalent vaccine, to new clinical data from a cutting-edge antibody-drug conjugate…

27 September 2024/in Insights

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi. London-based Vicebio said funding […]

Insights from Optimum’s 15th Annual Healthcare Investor Conference 2023

26 October 2023/in Insights

Optimum Strategic Communications celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! Optimism, preparation, and resilience, these were the key takeaways from our wonderful speakers on Wednesday 11 October at the Wellcome Trust. Check out our panel summaries below to learn more or to rediscover […]